Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing small molecule therapeutics designed to selectively degrade disease-causing proteins. The company harnesses the body's natural protein degradation system to target proteins that are difficult to address with traditional drugs. Its lead product candidate is KT-621, an oral STAT6 degrader currently in Phase 2b clinical trials for conditions such as moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, and BP. Additionally, Kymera is developing KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. The company also has an IRAK4 program (KT-485/SAR447971) in Phase II trials for immunology-inflammation diseases like hidradenitis suppurativa and atopic dermatitis, and a CDK2 program with potential in breast cancer and solid tumors.

Kymera Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol KYMR. The company's stock is traded in US dollars (USD), which is the official currency of the United States. As a US-based company listed on a major American exchange, its financial reporting and stock price are denominated in USD, making it accessible to investors trading in US markets.

Kymera Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies that leverage protein degradation technology to treat diseases. The company's work is at the intersection of biology and chemistry, aiming to create small molecule drugs that can selectively eliminate harmful proteins. This places Kymera among other biotech firms that are advancing novel treatment modalities for a range of conditions, from inflammatory diseases to cancer.

Kymera Therapeutics is headquartered in Watertown, Massachusetts, United States. The company was incorporated in 2015 and primarily serves the US market, though its clinical trials and potential future products target global health conditions. Its research and development efforts are focused on diseases that affect patients worldwide, including atopic dermatitis, asthma, COPD, autoimmune disorders, and various cancers. Through its strategic alliance with Sanofi S.A., Kymera also collaborates on developing drug candidates targeting IRAK4 outside oncology and immuno-oncology, indicating a broader international reach in its pipeline development.

Kymera Therapeutics operates as a clinical-stage biopharmaceutical company, generating value through the discovery and development of small molecule protein degraders. Its business model involves advancing its proprietary pipeline of drug candidates through preclinical and clinical stages, with the goal of eventually commercializing them or entering into licensing agreements. A notable partnership is a strategic alliance with Sanofi S.A., focused on developing drug candidates targeting IRAK4 for immunology-inflammation diseases, excluding oncology and immuno-oncology fields. This collaboration provides Kymera with resources and expertise to accelerate development. The company's portfolio includes multiple programs in various stages of clinical trials, such as KT-621, KT-579, and the IRAK4 program, which target a wide range of diseases from atopic dermatitis to breast cancer.